期刊文献+
共找到5篇文章
< 1 >
每页显示 20 50 100
Salvia Polyphenolates Combined with Doxophylline in the Treatment of Patients with Chronic Pulmonary Heart Disease in the Compensated Stage
1
作者 Meijuan Ma Fen Yang 《Journal of Clinical and Nursing Research》 2024年第5期52-55,共4页
Objective:To statistically determine the effect of salvia polyphenolates combined with doxophylline treatment in patients with chronic pulmonary heart disease in the compensated stage.Methods:From January 2023 to Janu... Objective:To statistically determine the effect of salvia polyphenolates combined with doxophylline treatment in patients with chronic pulmonary heart disease in the compensated stage.Methods:From January 2023 to January 2024,76 patients with chronic pulmonary heart disease in the compensated stage were selected as research subjects.The patients were divided into a research group and a reference group using a randomized numerical table method.The research group was treated with salvia polyphenolates combined with doxophylline,while the reference group received conventional therapy.The treatment effects of the two groups were compared.Results:The patients in the research group,treated with salvia polyphenolates combined with doxophylline,showed maximal ventilation of 73.26±4.83 L/min,left ventricular ejection fraction of 56.14±1.98%,and total effective treatment rate of 94.74%.These results were better than those of the reference group.The differences between the data of the research group and the reference group were statistically significant(P<0.05).Conclusion:For patients with chronic pulmonary heart disease in the compensated stage,treatment with salvia polyphenolates combined with doxophylline significantly improves maximum ventilation and left ventricular ejection fraction,and also results in a higher total effective treatment rate. 展开更多
关键词 Salvia polyphenolates Doxophylline chronic pulmonary heart disease in the compensated stage
下载PDF
Role of Voltage-gated Potassium Channels in Pathogenesis of Chronic Pulmonary Heart Disease 被引量:6
2
作者 柯琴梅 吴霁 +2 位作者 田莉 李伟 杜以梅 《Journal of Huazhong University of Science and Technology(Medical Sciences)》 SCIE CAS 2013年第5期644-649,共6页
The influence of hypoxia on the activity of voltage-gated potassium channel in pulmonary artery smooth muscle cells (PASMCs) of rats and its roles in the pathogenesis of chronic pulmonary heart disease were investig... The influence of hypoxia on the activity of voltage-gated potassium channel in pulmonary artery smooth muscle cells (PASMCs) of rats and its roles in the pathogenesis of chronic pulmonary heart disease were investigated. Eighty male Sprague-Dawley rats were randomly allocated into control group (n=10), acute hypoxic group (n=10), and chronic hypoxic groups (n=60). The chronic hypoxic groups were randomly divided into 6 subgroups (n=10 each) according to the chronic hypoxic periods. The rats in the control group were kept in room air and those in acute hypoxic group in hypoxia envi- ronmental chamber for 8 h. The rats in chronic hypoxic subgroups were kept in hypoxia environmental chamber for 8 h per day for 5, 10, 15, 20, 25, and 30 days, respectively. The mean pulmonary arterial pressure (mPAP), right ventricular hypertrophy index (RVHI), and the current of voltage-gated potas- sium channel (IK) in PASMCs were measured. Results showed that both acute and chronic hypoxia could decrease the IK in PASMCs of rats and the I-V relationship downward shifted to the right. And the peak Ir density at +60mV decreased with prolongation of hypoxia exposure. No significant difference was noted in the density oflK (at +60 mV) and I-V relationship between control group and chronic hy- poxic subgroup exposed to hypoxia for 5 days (P〉0.05), but there was a significant difference between control group and chronic hypoxic subgroup exposed to hypoxia for 10 days (P〈0.05). Significant dif- ferences were noted in the IK density (at +60 mV) and I-V relationships between control group and chronic hypoxic subgroups exposed to hypoxia for 20 days and 30 days (P〈0.01). Compared with con- trol rats, the mPAP and RVHI were significantly increased after chronic exposure to hypoxia for 10 days (P〈0.05), which were further increased with prolongation of hypoxia exposure, and there were signifi- cant differences between control group and chronic hypoxic subgroups exposed to hypoxia for 20 days and 30 days (P〈0.01). Both the mPAP and the RVHI were negatively correlated with the density OflK (r---0.89769 and -0.94476, respectively, both P〈0.01). It is concluded that exposure to hypoxia may cause decreased activity of voltage-gated potassium channel, leading to hypoxia pulmonary vasocon- striction (HPV). Sustained HPV may result in chronic pulmonary hypertension, even chronic pulmonary heart disease, contributing to the pathogenesis of chronic pulmonary heart disease. 展开更多
关键词 potassium channel chronic pulmonary heart disease hypoxia pulmonary vasoconstriction
下载PDF
PLATELET ACTIVATION IN PATIENTS WITH CHRONIC PULMONARY HEART DISEASE EFFECT OF DIPYRIDAMOLE TREATMENT
3
作者 张旭 凌培基 《Chinese Medical Journal》 SCIE CAS CSCD 1995年第2期17-19,共3页
Plasma levels of /f-thromboglobulin (/?-TG), platelet fac-tor 4(P and platelet aggregation rate (PAR) were measured in remission phase of 15 patients affected with chronic pulmonary heart disease (CPHD). 0-TG, /?-TG /... Plasma levels of /f-thromboglobulin (/?-TG), platelet fac-tor 4(P and platelet aggregation rate (PAR) were measured in remission phase of 15 patients affected with chronic pulmonary heart disease (CPHD). 0-TG, /?-TG / PF4, PF4 and PAR were significantly higher in the patients than in controls (/3<0.01 and 0.05, respectively). After 10 days of treatment with Dipyridamole lOOtng tid, fi-TG, /?-TG / PF4 and PF4 decreased significantly compared with pretreatment values (/><0.01 and 0.05, respectively). The results suggest that in vivo platelet activation is indeed present in patients with CPHD and that dipyridamole can antagonize platelet activation in vivo. 展开更多
关键词 CPHD In COPD PLATELET ACTIVATION IN PATIENTS WITH chronic PULMONARY heart disease EFFECT OF DIPYRIDAMOLE TREATMENT
原文传递
Randomized controlled trial of remote ischemic preconditioning and atrial fibrillation in patients undergoing cardiac surgery 被引量:1
4
作者 Amir S Lotfi Hossein Eftekhari +5 位作者 Auras R Atreya Ananth Kashikar Senthil K Sivalingam Miguel Giannoni Paul Visintainer Daniel Engelman 《World Journal of Cardiology》 CAS 2016年第10期615-622,共8页
AIM To study whether remote ischemic preconditioning(RIPC) has an impact on clinical outcomes, such as post-operative atrial fibrillation(POAF).METHODS This was a prospective, single-center, single-blinded,randomized ... AIM To study whether remote ischemic preconditioning(RIPC) has an impact on clinical outcomes, such as post-operative atrial fibrillation(POAF).METHODS This was a prospective, single-center, single-blinded,randomized controlled study. One hundred and two patients were randomized to receive RIPC(3 cycles of 5 min ischemia and 5 min reperfusion in the upper arm after induction of anesthesia) or no RIPC(control). Primary outcome was POAF lasting for five minutes or longer during the first seven days after surgery. Secondary outcomes included length of hospital stay, incidence of inpatient mortality, myocardial infarction, and stroke. RESULTS POAF occurred at a rate of 54% in the RIPC group and 41.2% in the control group(P = 0.23). No statistically significant differences were noted in secondary outcomes between the two groups. CONCLUSION This is the first study in the United States to suggest that RIPC does not reduce POAF in patients with elective or urgent cardiac surgery. There were no differences in adverse effects in either group. Further studies are required to assess the relationship between RIPC and POAF. 展开更多
关键词 chronic ischemic heart disease Cardiac surgery Coronary artery disease Other treatment Remote ischemic preconditioning Post-operative atrial fibrillation
下载PDF
PICCO检测在肺心病合并心源性休克中的应用价值分析 被引量:8
5
作者 董庆华 汤展宏 秦学斌 《重庆医学》 CAS 北大核心 2017年第23期3229-3230,3233,共3页
目的分析脉搏指示连续心输出量(PICCO)检测在慢性肺源性心脏病合并心源性休克中的应用价值。方法选择2014年1月至2015年3月该院收治的慢性肺源性心脏病合并心源性休克患者68例,分为研究组36例,对照组32例。两组均给予慢性肺源性心脏病... 目的分析脉搏指示连续心输出量(PICCO)检测在慢性肺源性心脏病合并心源性休克中的应用价值。方法选择2014年1月至2015年3月该院收治的慢性肺源性心脏病合并心源性休克患者68例,分为研究组36例,对照组32例。两组均给予慢性肺源性心脏病合并心源性休克常规治疗,对照组同时行深静脉穿刺监测患者中心静脉压(CVP)变化。研究组在常规监测基础上行深静脉置管+股动脉置管+PICCO监测。观察两组治疗效果及研究组治疗期间PICCO指标变化。结果研究组患者应用血管活性药物时间、住院时间、机械通气时间均显著低于对照组,差异有统计学意义(P<0.05),两组病死率比较差异无统计学意义(P>0.05)。治疗后研究组患者心输出量(CI)显著升高,血管外肺水指数(EVLWI)和PVPI显著降低,组间差异有统计学意义(P<0.05),组间胸腔内血容量(ITBVI)比较差异无统计学意义(P>0.05)。研究组中存活组CI显著高于死亡组,EVLWI和PVPI显著低于死亡组(P<0.05),两组ITBVI比较差异无统计学意义(P>0.05)。结论 PICCO可以反映慢性肺源性心脏病合并心源性休克患者血流动力学情况,对于指导患者治疗和预后判断具有重要的临床价值。 展开更多
关键词 肺心病 慢性病 休克 心原性 心排血量 预后
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部